Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront

July 9, 2026 10:36 AM EDT News Briefing Ipsen suc­ceeds in mi­graine tri­als; Tar­sus buys iRenix for $75M up­front ENDPOINTS Plus news on Alchemab, Sci­pher and Forte. 💉 Ipsen’s Dys­port aces Phase 3 mi­graine tri­als: The biotech’s in­jectable neu­ro­tox­in met … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER